<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37344560</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>21</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Serological and clinical associations of autoantibodies in Chinese patients with new-onset systemic lupus erythematosus.</ArticleTitle><Pagination><StartPage>10101</StartPage><MedlinePgn>10101</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">10101</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-023-37100-5</ELocationID><Abstract><AbstractText>To study the clinical significance of autoantibodies in Chinese patients with new-onset systemic lupus erythematosus (SLE), we enrolled 526 new-onset patients who met the 1997 Updated American College of Rheumatology SLE Classification Criteria for a retrospective cohort study. Chi-square test and Wilcoxon rank-sum test were used to detect the relationship of autoantibodies with clinical manifestations and serological results respectively. Our results demonstrated that the positive rate of anti-ribosomal P protein (anti-P) antibody in female patients was higher than that in male patients (41.2% vs. 22%, P&#x2009;=&#x2009;0.008). Patients with anti-SSB (43.95&#x2009;&#xb1;&#x2009;73.12 vs. 40.92&#x2009;&#xb1;&#x2009;75.75, P&#x2009;=&#x2009;0.004; 63.93&#x2009;&#xb1;&#x2009;103.56 vs. 55.06&#x2009;&#xb1;&#x2009;120.84, P&#x2009;=&#x2009;0.008 respectively) antibodies had higher levels of alanine aminotransferase (ALT) and aspartate transaminase (AST), whereas those with anti-P antibody (28.90&#x2009;&#xb1;&#x2009;25.70 vs. 50.08&#x2009;&#xb1;&#x2009;93.00, P&#x2009;=&#x2009;0.014; 38.51&#x2009;&#xb1;&#x2009;48.19 vs. 69.95&#x2009;&#xb1;&#x2009;142.67, P&#x2009;=&#x2009;0.047, respectively) had lower levels of them. Anti-dsDNA antibody (P&#x2009;=&#x2009;0.021) was associated with pulmonary arterial hypertension (PAH). The patients with anti-Ro60 (P&#x2009;=&#x2009;0.044), anti-P (P&#x2009;=&#x2009;0.012) and anti-dsDNA (P&#x2009;=&#x2009;0.013) antibodies were less likely to develop Interstitial lung disease. Anti-SmRNP antibody was correlated to lower prevalence of neuropsychiatric symptoms (P&#x2009;=&#x2009;0.037), and patients with anti-centromere antibody (ACA) were more likely to develop serositis (P&#x2009;=&#x2009;0.016).We identified five clusters of SLE-related autoantibodies, confirmed previously reported associations of autoantibodies, and discovered new associations.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gong</LastName><ForeName>Muxue</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233004, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dai</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233004, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Zhuobei</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233004, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Dengxiao</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233004, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ning</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233004, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Xiaoyun</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233004, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Changhao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, 233004, China. uglboy2002@126.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anhui Provincial Key Laboratory of Immunology in Chronic Diseases, Bengbu Medical College, Bengbu, 233003, China. uglboy2002@126.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000095225" MajorTopicYN="N">East Asian People</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012700" MajorTopicYN="Y">Serositis</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>22</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>21</Day><Hour>23</Hour><Minute>21</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37344560</ArticleId><ArticleId IdType="pmc">PMC10284812</ArticleId><ArticleId IdType="doi">10.1038/s41598-023-37100-5</ArticleId><ArticleId IdType="pii">10.1038/s41598-023-37100-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Olsen NJ, Karp DR. Autoantibodies and SLE: The threshold for disease. Nat. Rev. Rheumatol. 2014;10(3):181&#x2013;186. doi: 10.1038/nrrheum.2013.184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2013.184</ArticleId><ArticleId IdType="pubmed">24296678</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao ZX, Miller JS, Zheng SG. An updated advance of autoantibodies in autoimmune diseases. Autoimmun Rev. 2021;20(2):102743. doi: 10.1016/j.autrev.2020.102743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102743</ArticleId><ArticleId IdType="pubmed">33333232</ArticleId></ArticleIdList></Reference><Reference><Citation>Fava A, Petri M. Systemic lupus erythematosus: Diagnosis and clinical management. J. Autoimmun. 2019;96:1&#x2013;13. doi: 10.1016/j.jaut.2018.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2018.11.001</ArticleId><ArticleId IdType="pmc">PMC6310637</ArticleId><ArticleId IdType="pubmed">30448290</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. doi: 10.1002/art.1780400928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Xia Y. Anti-double stranded DNA antibodies: Origin, pathogenicity, and targeted therapies. Front. Immunol. 2019;10:1667. doi: 10.3389/fimmu.2019.01667.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01667</ArticleId><ArticleId IdType="pmc">PMC6650533</ArticleId><ArticleId IdType="pubmed">31379858</ArticleId></ArticleIdList></Reference><Reference><Citation>Sulcebe G, Morcka K. Diagnostic and prognostic significance of different antinuclear antibodies in more than 1000 consecutive Albanian patients with rheumatic diseases. Clin. Exp. Rheumatol. 1992;10(3):255&#x2013;261.</Citation><ArticleIdList><ArticleId IdType="pubmed">1582070</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao L, Liu G, Li C, Li Y, Wang Z, Zhou Z, Tong S, Wu X. Specificity of anti-SSB as a diagnostic marker for the classification of systemic lupus erythematosus. Exp. Ther. Med. 2013;5(6):1710&#x2013;1714. doi: 10.3892/etm.2013.1051.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/etm.2013.1051</ArticleId><ArticleId IdType="pmc">PMC3702711</ArticleId><ArticleId IdType="pubmed">23837059</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnaud L, Mathian A, Boddaert J, Amoura Z. Late-onset systemic lupus erythematosus: Epidemiology, diagnosis and treatment. Drugs Aging. 2012;29(3):181&#x2013;189. doi: 10.2165/11598550-000000000-00000.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11598550-000000000-00000</ArticleId><ArticleId IdType="pubmed">22263748</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn A, Bonsmann G, Anders HJ, Herzer P, Tenbrock K, Schneider M. The diagnosis and treatment of systemic lupus erythematosus. Deutsches Arzteblatt Int. 2015;112(25):423&#x2013;432. doi: 10.3238/arztebl.2015.0423.</Citation><ArticleIdList><ArticleId IdType="doi">10.3238/arztebl.2015.0423</ArticleId><ArticleId IdType="pmc">PMC4558874</ArticleId><ArticleId IdType="pubmed">26179016</ArticleId></ArticleIdList></Reference><Reference><Citation>Metry AM, Al Salmi I, Al Balushi F, Yousef MA, Al Ismaili F, Hola A, Hannawi S. Systemic lupus erythematosus: Symptoms and signs at initial presentations. AntiInflamm. Antiallergy Agents Med. Chem. 2019;18(2):142&#x2013;150. doi: 10.2174/1871523018666181128161828.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871523018666181128161828</ArticleId><ArticleId IdType="pubmed">30488801</ArticleId></ArticleIdList></Reference><Reference><Citation>Sebastiani GD, Prevete I, Iuliano A, Minisola G. The importance of an early diagnosis in systemic lupus erythematosus. Isr. Med. Assoc. J. IMAJ. 2016;18(3&#x2013;4):212&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">27228646</ArticleId></ArticleIdList></Reference><Reference><Citation>Nossent J, Kiss E, Rozman B, Pokorny G, Vlachoyiannopoulos P, Olesinska M, Marchesoni A, Mosca M, P&#xe5;i S, Manger K, Schneider M, Nielsen H, van Vollenhoven R, Swaak T. Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus. 2010;19(8):949&#x2013;956. doi: 10.1177/0961203310366572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203310366572</ArticleId><ArticleId IdType="pubmed">20375124</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuchten N, Milke B, Winkler-Rohlfing B, Daikh D, D&#xf6;rner T, Johnson SR, Aringer M, on behalf of the SLE Classification Criteria Steering Committee Early symptoms of systemic lupus erythematosus (SLE) recalled by 339 SLE patients. Lupus. 2018;27(9):1431&#x2013;1436. doi: 10.1177/0961203318776093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203318776093</ArticleId><ArticleId IdType="pubmed">29771193</ArticleId></ArticleIdList></Reference><Reference><Citation>Hannah JR, D'Cruz DP. Pulmonary complications of systemic lupus erythematosus. Sem. Respir. Crit. Care Med. 2019;40(2):227&#x2013;234. doi: 10.1055/s-0039-1685537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0039-1685537</ArticleId><ArticleId IdType="pubmed">31137062</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisetsky DS, Bossuyt X, Meroni PL. ANA as an entry criterion for the classification of SLE. Autoimmun. Rev. 2019;18(12):102400. doi: 10.1016/j.autrev.2019.102400.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2019.102400</ArticleId><ArticleId IdType="pubmed">31639513</ArticleId></ArticleIdList></Reference><Reference><Citation>Dema B, Charles N. Autoantibodies in SLE: Specificities, isotypes and receptors. Antibodies (Basel Switz.) 2016;5(1):2. doi: 10.3390/antib5010002.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antib5010002</ArticleId><ArticleId IdType="pmc">PMC6698872</ArticleId><ArticleId IdType="pubmed">31557984</ArticleId></ArticleIdList></Reference><Reference><Citation>Flechsig A, Rose T, Barkhudarova F, Strauss R, Klotsche J, D&#xe4;hnrich C, Schlumberger W, Enghard P, Burmester GR, Hiepe F, Biesen R. What is the clinical significance of anti-Sm antibodies in systemic lupus erythematosus? A comparison with anti-dsDNA antibodies and C3. Clin. Exp. Rheumatol. 2017;35(4):598&#x2013;606.</Citation><ArticleIdList><ArticleId IdType="pubmed">28281463</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham M, Derk CT. Anti-ribosomal-P antibodies in lupus nephritis, neuropsychiatric lupus, lupus hepatitis, and Chagas&#x2019; disease: Promising yet limited in clinical utility. Rheumatol. Int. 2015;35(1):27&#x2013;33. doi: 10.1007/s00296-014-3058-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-014-3058-3</ArticleId><ArticleId IdType="pubmed">24906575</ArticleId></ArticleIdList></Reference><Reference><Citation>Didier K, Bolko L, Giusti D, Toquet S, Robbins A, Antonicelli F, Servettaz A. Autoantibodies associated with connective tissue diseases: What meaning for clinicians? Front. Immunol. 2018;9:541. doi: 10.3389/fimmu.2018.00541.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00541</ArticleId><ArticleId IdType="pmc">PMC5879136</ArticleId><ArticleId IdType="pubmed">29632529</ArticleId></ArticleIdList></Reference><Reference><Citation>Burlingame RW, Cervera R. Anti-chromatin (anti-nucleosome) autoantibodies. Autoimmun. Rev. 2002;1(6):321&#x2013;328. doi: 10.1016/s1568-9972(02)00083-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1568-9972(02)00083-6</ArticleId><ArticleId IdType="pubmed">12848987</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasoto SG, Viana VS, Bonfa E. The clinical utility of anti-ribosomal P autoantibodies in systemic lupus erythematosus. Expert Rev. Clin. Immunol. 2014;10(11):1493&#x2013;1503. doi: 10.1586/1744666X.2014.966692.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/1744666X.2014.966692</ArticleId><ArticleId IdType="pubmed">25292164</ArticleId></ArticleIdList></Reference><Reference><Citation>Conti F, Ceccarelli F, Perricone C, Massaro L, Marocchi E, Miranda F, Spinelli FR, Truglia S, Alessandri C, Valesini G. Systemic Lupus Erythematosus with and without Anti-dsDNA antibodies: Analysis from a large monocentric cohort. Med. Inflamm. 2015;2015:328078. doi: 10.1155/2015/328078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/328078</ArticleId><ArticleId IdType="pmc">PMC4438145</ArticleId><ArticleId IdType="pubmed">26063969</ArticleId></ArticleIdList></Reference><Reference><Citation>Correa-Rodr&#xed;guez M, Pocovi-Gerardino G, Callejas-Rubio JL, R&#xed;os-Fern&#xe1;ndez R, Mart&#xed;n-Amada M, Cruz-Caparr&#xf3;s MG, Rueda-Medina B, Ortego-Centeno N. Clinical and serological associations of autoantibodies in patients with systemic lupus erythematosus. J. Investig. Med. Off. Publ. Am. Fed. Clin. Res. 2021;69(8):1417&#x2013;1425. doi: 10.1136/jim-2021-001887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jim-2021-001887</ArticleId><ArticleId IdType="pubmed">34183445</ArticleId></ArticleIdList></Reference><Reference><Citation>Vil&#xe1; LM, Molina MJ, Mayor AM, Peredo RA, Santaella ML, Vil&#xe1; S. Clinical and prognostic value of autoantibodies in puerto Ricans with systemic lupus erythematosus. Lupus. 2006;15(12):892&#x2013;898. doi: 10.1177/0961203306069352.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203306069352</ArticleId><ArticleId IdType="pubmed">17211998</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M. Inflammatory markers in systemic lupus erythematosus. J. Autoimmun. 2020;110:102374. doi: 10.1016/j.jaut.2019.102374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2019.102374</ArticleId><ArticleId IdType="pubmed">31812331</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Wang Q, Zhao J, Li Z, Ye Z, Li C, Li X, Zhu P, Wang Z, Zheng Y, Li X, Zhang M, Tian Z, Liu Y, He J, Zhang F, Zhao Y, Zeng X, CSTAR co-authors, Chinese SLE treatment and research group (CSTAR) registry: II. Prevalence and risk factors of pulmonary arterial hypertension in Chinese patients with systemic lupus erythematosus. Lupus. 2014;23(10):1085&#x2013;1091. doi: 10.1177/0961203314527366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203314527366</ArticleId><ArticleId IdType="pubmed">24651670</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez P, Mozo L, Guti&#xe9;rrez C, Su&#xe1;rez A. Epidemiology of systemic lupus erythematosus in a northern Spanish population: Gender and age influence on immunological features. Lupus. 2003;12(11):860&#x2013;865. doi: 10.1191/0961203303lu469xx.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/0961203303lu469xx</ArticleId><ArticleId IdType="pubmed">14667105</ArticleId></ArticleIdList></Reference><Reference><Citation>Arroyo-&#xc1;vila M, Santiago-Casas Y, McGwin G, Jr, Cantor RS, Petri M, Ramsey-Goldman R, Reveille JD, Kimberly RP, Alarc&#xf3;n GS, Vil&#xe1; LM, Brown EE. Clinical associations of anti-Smith antibodies in PROFILE: A multi-ethnic lupus cohort. Clin. Rheumatol. 2015;34(7):1217&#x2013;1223. doi: 10.1007/s10067-015-2941-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-015-2941-y</ArticleId><ArticleId IdType="pmc">PMC4475431</ArticleId><ArticleId IdType="pubmed">25896533</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn SS, Jung SM, Yoo J, Lee SW, Song JJ, Park YB. Anti-Smith antibody is associated with disease activity in patients with new-onset systemic lupus erythematosus. Rheumatol. Int. 2019;39(11):1937&#x2013;1944. doi: 10.1007/s00296-019-04445-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-019-04445-y</ArticleId><ArticleId IdType="pubmed">31552434</ArticleId></ArticleIdList></Reference><Reference><Citation>Alba P, Bento L, Cuadrado MJ, Karim Y, Tungekar MF, Abbs I, Khamashta MA, D'Cruz D, Hughes GR. Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: Significant factors associated with lupus nephritis. Ann. Rheum. Dis. 2003;62(6):556&#x2013;560. doi: 10.1136/ard.62.6.556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.62.6.556</ArticleId><ArticleId IdType="pmc">PMC1754557</ArticleId><ArticleId IdType="pubmed">12759294</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni JD, Yao X, Pan HF, Li XP, Xu JH, Ye DQ. Clinical and serological correlates of anti-Sm autoantibodies in Chinese patients with systemic lupus erythematosus: 1,584 cases. Rheumatol. Int. 2009;29(11):1323&#x2013;1326. doi: 10.1007/s00296-009-0855-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-009-0855-1</ArticleId><ArticleId IdType="pubmed">19194707</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh RR, Malaviya AN, Kailash S, Varghese T. Clinical significance of anti-Sm antibody in systemic lupus erythematosus &amp; related disorders. Indian J. Med. Res. 1991;94:206&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">1834551</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez-Longo FJ, Gonz&#xe1;lez Fern&#xe1;ndez CM, Rodr&#xed;guez Mahou M, Grau Sim&#xf3; R, Monteagudo S&#xe1;ez I, Meno Garc&#xed;a AC, Carre&#xf1;o P&#xe9;rez L. Expresi&#xf3;n cl&#xed;nica del lupus eritematoso sist&#xe9;mico con anticuerpos anti-U1-RNP y anti-Sm [Clinical expression of systemic lupus erythematosus with anti-U1-RNP and anti-Sm antibodies] Rev. Clin. Esp. 1997;197(5):329&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pubmed">9280966</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahler M, Agmon-Levin N, van Liempt M, Shoenfeld Y, Waka A, Hiepe F, Swart A, G&#xfc;rtler I, Fritzler MJ. Multi-center evaluation of autoantibodies to the major ribosomal P C22 epitope. Rheumatol. Int. 2012;32(3):691&#x2013;698. doi: 10.1007/s00296-010-1685-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-010-1685-x</ArticleId><ArticleId IdType="pubmed">21140265</ArticleId></ArticleIdList></Reference><Reference><Citation>Briani C, Lucchetta M, Ghirardello A, Toffanin E, Zampieri S, Ruggero S, Scarlato M, Quattrini A, Bassi N, Ermani M, Battistin L, Doria A. Neurolupus is associated with anti-ribosomal P protein antibodies: An inception cohort study. J. Autoimmun. 2009;32(2):79&#x2013;84. doi: 10.1016/j.jaut.2008.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2008.12.002</ArticleId><ArticleId IdType="pubmed">19171463</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahler M, Kessenbrock K, Szmyrka M, Takasaki Y, Garcia-De La Torre I, Shoenfeld Y, Hiepe F, Shun-le C, von M&#xfc;hlen CA, Locht H, H&#xf6;pfl P, Wiik A, Reeves W, Fritzler MJ. International multicenter evaluation of autoantibodies to ribosomal P proteins. Clin. Vaccine Immunol. CVI. 2006;13(1):77&#x2013;83. doi: 10.1128/CVI.13.1.77-83.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.13.1.77-83.2006</ArticleId><ArticleId IdType="pmc">PMC1356623</ArticleId><ArticleId IdType="pubmed">16426003</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerli R, Caponi L. Anti-ribosomal P protein antibodies. Autoimmunity. 2005;38(1):85&#x2013;92. doi: 10.1080/08916930400022699.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08916930400022699</ArticleId><ArticleId IdType="pubmed">15804709</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiss E, Shoenfeld Y. Are anti-ribosomal P protein antibodies relevant in systemic lupus erythematosus? Clin. Rev. Allergy Immunol. 2007;32(1):37&#x2013;46. doi: 10.1007/BF02686080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02686080</ArticleId><ArticleId IdType="pubmed">17426359</ArticleId></ArticleIdList></Reference><Reference><Citation>Reichlin M. Autoantibodies to the ribosomal P proteins in systemic lupus erythematosus. Clin. Exp. Med. 2006;6(2):49&#x2013;52. doi: 10.1007/s10238-006-0094-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10238-006-0094-7</ArticleId><ArticleId IdType="pubmed">16820990</ArticleId></ArticleIdList></Reference><Reference><Citation>Harley JB, Scofield RH, Reichlin M. Anti-Ro in Sj&#xf6;gren&#x2019;s syndrome and systemic lupus erythematosus. Rheumatic diseases clinics of North America. 1992;18(2):337&#x2013;358. doi: 10.1016/S0889-857X(21)00731-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0889-857X(21)00731-6</ArticleId><ArticleId IdType="pubmed">1626073</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulware DW, Hedgpeth MT. Lupus pneumonitis and anti-SSA (Ro) antibodies. J. Rheumatol. 1989;16(4):479&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pubmed">2664170</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Leng X, Li Z, Ye Z, Li C, Li X, Zhu P, Wang Z, Zheng Y, Li X, Zhang M, Tian XP, Li M, Zhao J, Zhang FC, Zhao Y, Zeng X. Chinese SLE treatment and research group registry: III. Association of autoantibodies with clinical manifestations in Chinese patients with systemic lupus erythematosus. J. Immunol. Res. 2014;2014:809389. doi: 10.1155/2014/809389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/809389</ArticleId><ArticleId IdType="pmc">PMC4017718</ArticleId><ArticleId IdType="pubmed">24864270</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;mez-Puerta JA, Burlingame RW, Cervera R. Anti-chromatin (anti-nucleosome) antibodies: Diagnostic and clinical value. Autoimmun. Rev. 2008;7(8):606&#x2013;611. doi: 10.1016/j.autrev.2008.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2008.06.005</ArticleId><ArticleId IdType="pubmed">18606252</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller S, Dieker J, Tincani A, Meroni PL. Pathogenic anti-nucleosome antibodies. Lupus. 2008;17(5):431&#x2013;436. doi: 10.1177/0961203308090030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203308090030</ArticleId><ArticleId IdType="pubmed">18490422</ArticleId></ArticleIdList></Reference><Reference><Citation>Migliorini P, Ardman B, Kaburaki J, Schwartz RS. Parallel sets of autoantibodies in MRL-lpr/lpr mice. An anti-DNA, anti-SmRNP, anti-gp70 network. J. Exp. Med. 1987;165(2):483&#x2013;499. doi: 10.1084/jem.165.2.483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.165.2.483</ArticleId><ArticleId IdType="pmc">PMC2188508</ArticleId><ArticleId IdType="pubmed">2950197</ArticleId></ArticleIdList></Reference><Reference><Citation>Migliorini P, Baldini C, Rocchi V, Bombardieri S. Anti-Sm and anti-RNP antibodies. Autoimmunity. 2005;38(1):47&#x2013;54. doi: 10.1080/08916930400022715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08916930400022715</ArticleId><ArticleId IdType="pubmed">15804705</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman IE, Peene I, Meheus L, Huizinga TW, Cebecauer L, Isenberg D, De Bosschere K, Hulstaert F, Veys EM, De Keyser F. Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus. Ann. Rheum. Dis. 2004;63(9):1155&#x2013;1158. doi: 10.1136/ard.2003.013417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2003.013417</ArticleId><ArticleId IdType="pmc">PMC1755119</ArticleId><ArticleId IdType="pubmed">15308527</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi MY, Clarke AE, Urowitz M, Hanly J, St-Pierre Y, Gordon C, Bae SC, Romero-Diaz J, Sanchez-Guerrero J, Bernatsky S, Wallace DJ, Isenberg D, Rahman A, Merrill JT, Fortin PR, Gladman DD, Bruce IN, Petri M, Ginzler EM, Dooley MA, Fritzler MJ. Longitudinal analysis of ANA in the systemic lupus international collaborating clinics (SLICC) inception cohort. Ann. Rheum. Dis. 2022;81(8):1143&#x2013;1150. doi: 10.1136/annrheumdis-2022-222168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2022-222168</ArticleId><ArticleId IdType="pmc">PMC10066935</ArticleId><ArticleId IdType="pubmed">35338033</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>